| Autor: |
Kim S; Novartis Pharmaceuticals, East Hanover, New Jersey 07936, USA., LaMontagne K, Sabio M, Sharma S, Versace RW, Yusuff N, Phillips PE |
| Jazyk: |
angličtina |
| Zdroj: |
Cancer research [Cancer Res] 2004 May 01; Vol. 64 (9), pp. 2984-7. |
| DOI: |
10.1158/0008-5472.can-04-0019 |
| Abstrakt: |
Inhibition of endothelial cell growth by fumagillin has been assumed to be mediated by inhibition of the molecular target methionine aminopeptidase 2 (MetAp2). New data show that depletion of MetAp2 by siRNA does not inhibit endothelial cell growth. Moreover, MetAp2-depleted endothelial cells remain responsive to inhibition by either fumagillin or a newly identified MetAp2 enzyme inhibitor. These data suggest that MetAp2 function is not required for endothelial cell proliferation. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
